Alamar Biosciences (NASDAQ:ALMR) Major Shareholder Sells $1,310,871.20 in Stock

Alamar Biosciences, Inc. (NASDAQ:ALMR) major shareholder Corporate Gp Vi Ltd. Qiming sold 43,930 shares of the stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $29.84, for a total value of $1,310,871.20. Following the sale, the insider directly owned 160,913 shares of the company’s stock, valued at approximately $4,801,643.92. This trade represents a 21.45% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Corporate Gp Vi Ltd. Qiming also recently made the following trade(s):

• On Tuesday, November 3rd, Corporate Gp Vi Ltd. Qiming sold 111,313 shares of Alamar Biosciences stock. The stock was sold at an average price of $29.89, for a total transaction of $3,327,145.57.
• On Friday, October 30th, Corporate Gp Vi Ltd. Qiming sold 143,706 shares of Alamar Biosciences stock. The stock was sold at an average price of $30.38, for a total transaction of $4,365,788.28.
• On Wednesday, October 28th, Corporate Gp Vi Ltd. Qiming sold 100,837 shares of Alamar Biosciences stock. The shares were sold at an average price of $32.77, for a total transaction of $3,304,428.49.
• On Tuesday, October 27th, Corporate Gp Vi Ltd. Qiming sold 84,894 shares of Alamar Biosciences stock. The shares were sold at an average price of $31.39, for a total transaction of $2,664,822.66.
• On Monday, October 26th, Corporate Gp Vi Ltd. Qiming sold 132,524 shares of Alamar Biosciences stock. The shares were sold at an average price of $30.52, for a total transaction of $4,044,632.48.
• On Friday, October 23rd, Corporate Gp Vi Ltd. Qiming sold 147,934 shares of Alamar Biosciences stock. The shares were sold at an average price of $30.59, for a total transaction of $4,525,301.06.
• On Thursday, October 22nd, Corporate Gp Vi Ltd. Qiming sold 133,811 shares of Alamar Biosciences stock. The shares were sold at an average price of $29.33, for a total transaction of $3,924,676.63.
• On Wednesday, October 21st, Corporate Gp Vi Ltd. Qiming sold 208,815 shares of Alamar Biosciences stock. The shares were sold at an average price of $30.31, for a total transaction of $6,329,182.65.
• On Tuesday, October 20th, Corporate Gp Vi Ltd. Qiming sold 142,004 shares of Alamar Biosciences stock. The stock was sold at an average price of $27.89, for a total transaction of $3,960,491.56.
• On Monday, October 19th, Corporate Gp Vi Ltd. Qiming sold 75,508 shares of Alamar Biosciences stock. The stock was sold at an average price of $26.34, for a total transaction of $1,988,880.72.

Alamar Biosciences Price Performance

NASDAQ ALMR opened at $26.91 on Friday. The company has a quick ratio of 10.23, a current ratio of 11.85 and a debt-to-equity ratio of 0.03. The company has a market capitalization of $1.87 billion and a PE ratio of -13.73. Alamar Biosciences, Inc. has a 1 year low of $18.84 and a 1 year high of $39.61. The business has a 50-day simple moving average of $30.24.

Alamar Biosciences (NASDAQ:ALMR) last announced its quarterly earnings results on Wednesday, November 4th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.03. The business had revenue of $33.55 million for the quarter. As a group, equities research analysts anticipate that Alamar Biosciences, Inc. will post -1.22 earnings per share for the current year.

Key Alamar Biosciences News

Here are the key news stories impacting Alamar Biosciences this week:

• Positive Sentiment: Alamar reported third-quarter revenue of $33.55 million, up 68%, and a loss of $0.19 per share—narrower than analysts’ expected $0.22 loss. It also raised its 2026 revenue outlook to $121 million–$123 million, supporting its growth outlook. Q3 revenue and guidance
• Positive Sentiment: Alamar and GSK are collaborating on a large-scale proteomics study using Alamar’s platform. The research could increase the platform’s visibility, though no financial terms were disclosed. Alamar and GSK study
• Positive Sentiment: Analysts raised their price targets: TD Cowen lifted its target to $36 and maintained a Buy rating, while BofA Securities raised its target to $35 from $31. These moves indicate improved analyst expectations, though targets are not guarantees. TD Cowen price target BofA Securities price target
• Neutral Sentiment: The company plans to participate in upcoming investor conferences; the announcement did not include new financial guidance or other material business updates. Investor conferences announcement
• Negative Sentiment: Major shareholder Corporate Gp Vi Ltd. Qiming sold 111,313 shares on Nov. 3, after selling 43,930 shares on Nov. 2. The repeated sales—and the reduction in its reported ownership—could add supply and pressure sentiment; the filings do not give a reason for the sales. SEC filing on shareholder sale

Institutional Trading of Alamar Biosciences

Institutional investors and hedge funds have recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. purchased a new position in shares of Alamar Biosciences during the 3rd quarter worth approximately $196,000. Squarepoint Ops LLC bought a new position in shares of Alamar Biosciences in the 2nd quarter worth approximately $283,000. Sumitomo Mitsui Trust Group Inc. lifted its stake in shares of Alamar Biosciences by 18.5% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 66,913 shares of the company’s stock valued at $2,280,000 after purchasing an additional 10,461 shares during the period. State Street Corp purchased a new position in shares of Alamar Biosciences in the 2nd quarter valued at approximately $3,930,000. Finally, Wellington Management Group LLP purchased a new position in shares of Alamar Biosciences in the 2nd quarter valued at approximately $12,407,000.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on ALMR shares. Stifel Nicolaus upped their target price on Alamar Biosciences from $28.00 to $32.00 and gave the company a “buy” rating in a report on Tuesday, August 11th. JPMorgan Chase & Co. lifted their price target on shares of Alamar Biosciences from $32.00 to $35.00 and gave the company an “overweight” rating in a report on Tuesday, August 11th. Weiss Ratings downgraded shares of Alamar Biosciences from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, October 23rd. Finally, TD Cowen boosted their price objective on shares of Alamar Biosciences from $34.00 to $36.00 and gave the company a “buy” rating in a research report on Wednesday. Four analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $33.00.

Alamar Biosciences Company Profile

Alamar Biosciences, Inc (NASDAQ: ALMR) is a life sciences company focused on advancing proteomics and enabling earlier detection, diagnosis and monitoring of disease. The company develops technologies designed to measure very low levels of proteins in biological samples, supporting research in areas such as oncology, neurology, immunology and other complex diseases.

Its primary technology is the NULISA platform, a highly sensitive, multiplexed immunoassay system that combines affinity-based protein detection with digital counting.